- Home
- RCS vs KROS Comparison
RCS vs KROS Comparison
Compare RCS & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RCS | KROS |
|---|---|---|
| Founded | 1994 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 248.4M | 206.0M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | RCS | KROS |
|---|---|---|
| Price | $5.29 | $10.69 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $21.86 |
| AVG Volume (30 Days) | 121.7K | ★ 313.0K |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | ★ 10.12% | N/A |
| EPS Growth | N/A | ★ 146.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $243,864,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2,751.79 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.09 | $9.69 |
| 52 Week High | $8.00 | $22.55 |
Technical Indicators
Market Signals| Indicator | RCS | KROS |
|---|---|---|
| Relative Strength Index (RSI) | 41.20 | 46.57 |
| Support Level | $5.09 | $10.14 |
| Resistance Level | $5.67 | $11.55 |
| Average True Range (ATR) | 0.10 | 0.58 |
| MACD | -0.02 | -0.06 |
| Stochastic Oscillator | 6.25 | 17.91 |
Price Performance
Historical ComparisonAbout RCS PIMCO Strategic Income Fund Inc.
PIMCO Strategic Income Fund, Inc. operates as a closed-end management investment company. Its primary investment objective is to generate a level of income that is higher than that generated by high-quality, intermediate-term U.S. debt securities. The Fund also seeks capital appreciation to the extent consistent with the objective.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.